Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Tecvayli
Tecvayli has been authorised by the EMA for multiple myeloma.
-
EMA approval · 2026-08-26EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
EMA authorised Blenrep (belantamab mafodotin) for multiple myeloma, with GSK as the marketing authorisation holder.
-
EMA approval · 2026-08-26EMA Authorised: Darzalex (daratumumab)
Daratumumab (Darzalex) has been authorised by the EMA for its indicated use in multiple myeloma.
-
EMA approval · 2026-08-26EMA Authorised: Neofordex (dexamethasone) — THERAVIA
NEOFORDEX (dexamethasone) has been authorised for use in the European market by THERAVIA for multiple myeloma.
-
EMA approval · 2026-08-07EMA Authorised: Tecvayli
Tecvayli has been authorised in the EU for multiple myeloma with conditional approval.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-05EMA Authorised: Nexpovio (selinexor) — Stemline Therapeutics B.V.
Nexpovio (selinexor) has been authorised by the EMA for therapeutic use, with multiple myeloma as a indicated disease area.
-
EMA approval · 2026-08-05EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S
Ninlaro (ixazomib citrate) has been authorised in the EU for multiple myeloma by Takeda Pharma A/S.
-
EMA approval · 2026-08-05EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.
Kyprolis (carfilzomib) has been authorised by the EMA for multiple myeloma, with accelerated assessment.
-
EMA approval · 2026-07-22EMA Authorised: Plerixafor Accord (Plerixafor) — Accord Healthcare S.L.U.
The EMA authorises Plerixafor Accord for use in multiple myeloma and hematopoietic stem cell transplantation with Accord Healthcare S.L.U. a…
-
EMA approval · 2026-07-21EMA Authorised: Darzalex (daratumumab)
EMA authorised Darzalex (daratumumab) for use in multiple myeloma with orphan designation and accelerated assessment.
-
EMA approval · 2026-07-10EMA Authorised: Neofordex (dexamethasone) — THERAVIA
European Medicines Agency authorised Neofordex (dexamethasone) for therapeutic use, with THERAVIA as the marketing authorization holder, in …
-
EMA approval · 2026-07-07EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
EMA authorises Sarclisa (isatuximab) for multiple myeloma, expanding treatment options in this area.
-
CLINICAL_TRIALS research · 2026-07-02Clinical Trial Results: Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health [NA]
Clinical trial results for adapting multiple behavior interventions to improve cancer survivor health; completed with results posted.
-
EMA approval · 2026-06-24EMA Authorised: Tecvayli — Janssen-Cilag International N.V.
The EMA has authorised Tecvayli (Janssen-Cilag) for multiple myeloma under conditional approval.
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Update: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial update comparing bb2121 to standard regimens in relapsed/refractory multiple myeloma; completed study evaluating efficacy and …
-
EMA approval · 2026-06-12EMA Authorised: Lenalidomide Mylan (lenalidomide) — Mylan Pharmaceuticals Limited
Lenalidomide Mylan has been authorised in the EU for use in multiple myeloma.
-
EMA approval · 2026-06-09EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
EMA authorises Sarclisa (isatuximab) for multiple myeloma.
-
EMA approval · 2026-06-09EMA Authorised: Neofordex (dexamethasone) — THERAVIA
EMA authorises Neofordex (dexamethasone) for multiple myeloma under THERAVIA.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment [Phase 3]
Phase 3 trial evaluating talquetamab in combination with daratumumab (with or without pomalidomide) versus daratumumab-based regimen in mult…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]
Phase 3 trial assessing VRd followed by cilta-cel CAR-T versus Rd therapy in newly diagnosed multiple myeloma patients not planned for autol…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Results: Fluoroquinolone Resistance Prevalence Study
A terminated clinical trial study assessing fluoroquinolone resistance prevalence in the context of multiple myeloma; results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]
Phase 2 trial evaluating siltuximab for treating cytokine release syndrome and ICANS associated with CAR-T cell therapy; study completed wit…
-
EMA approval · 2026-04-28EMA Authorised: Darzalex (daratumumab) — Janssen-Cilag International N.V.
Authorised status for Darzalex (daratumumab) in the European Union for multiple myeloma with accelerated assessment and orphan designation.
-
EMA approval · 2026-04-24EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cance…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…